Buys | $0 | 0 | 0 |
Sells | $800,231 | 2 | 100 |
Smith Beth Ann | VP, Controller & Treasurer | 0 | $0 | 1 | $1,083 | $-1,083 |
Peters Jeffrey Stuart | Senior VP and General Counsel | 0 | $0 | 1 | $799,148 | $-799,148 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug …
Over the last 12 months, insiders at MacroGenics, Inc. have bought $0 and sold $800,231 worth of MacroGenics, Inc. stock.
On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $12.92M and sold $1.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $669,585 was made by BIOTECH TARGET N V (10 percent owner) on 2023‑10‑02.
2025-02-15 | Sale | Smith Beth Ann | VP, Controller & Treasurer | 423 0.0007% | $2.56 | $1,083 | +0.54% | |
2024-04-04 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 51,395 0.0725% | $15.55 | $799,148 | -79.89% | |
2024-03-06 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 19,625 0.0317% | $21.50 | $421,938 | -82.98% | |
2024-03-04 | Sale | Karrels James | SVP, CFO and Secretary | 30,000 0.0481% | $20.50 | $615,000 | -82.17% | |
2024-03-04 | Sale | Risser Eric Blasius | Chief Operating Officer | 41,159 0.0636% | $19.76 | $813,501 | -82.17% | |
2024-03-04 | Sale | Spitznagel Thomas | Sr VP, Technical Ops | 10,000 0.0156% | $20.00 | $200,000 | -82.17% | |
2024-02-26 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 16,124 0.0266% | $17.22 | $277,655 | -77.57% | |
2024-02-07 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 3,334 0.0069% | $18.00 | $60,012 | -76.65% | |
2024-02-05 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 76,251 0.1454% | $16.50 | $1.26M | -75.52% | |
2024-02-01 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0231% | $15.00 | $199,740 | -73.02% | |
2024-01-19 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 13,316 0.0216% | $12.00 | $159,792 | -64.71% | |
2023-12-20 | Sale | Bonvini Ezio | Sr VP, Research & CSO | 18,880 0.031% | $10.08 | $190,310 | -54.68% | |
2023-10-02 | BIOTECH TARGET N V | 10 percent owner | 150,000 0.2413% | $4.46 | $669,585 | +42.19% | ||
2023-09-07 | BIOTECH TARGET N V | 10 percent owner | 200,000 0.324% | $5.26 | $1.05M | +20.64% | ||
2023-08-30 | HURWITZ EDWARD | director | 15,000 0.0244% | $4.91 | $73,650 | +30.00% | ||
2023-03-10 | Sale | Peters Jeffrey Stuart | Senior VP and General Counsel | 5,372 0.0099% | $6.03 | $32,393 | +19.64% | |
2023-02-14 | BIOTECH TARGET N V | 10 percent owner | 500,000 0.7819% | $5.07 | $2.53M | +15.84% | ||
2023-01-19 | BIOTECH TARGET N V | director | 150,000 0.245% | $5.30 | $794,925 | +10.10% | ||
2022-12-27 | BIOTECH TARGET N V | director | 200,000 0.3249% | $5.61 | $1.12M | +1.25% | ||
2022-12-23 | BIOTECH TARGET N V | director | 200,000 0.3225% | $5.88 | $1.18M | -4.55% |
BIOTECH TARGET N V | 10 percent owner | 9929963 15.8213% | $22.04M | 19 | 0 | <0.0001% |
Karrels James | SVP, CFO and Secretary | 171452 0.2732% | $380,623.44 | 1 | 3 | +137.87% |
Costa Paulo F | director | 59435 0.0947% | $131,945.70 | 1 | 0 | +41.83% |
HURWITZ EDWARD | director | 33074 0.0527% | $73,424.28 | 1 | 1 | +30% |
Galbraith Kenneth | director | 0 0% | $0 | 1 | 1 | <0.0001% |
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$16,245,616 | 40 | 123.58% | $122.63M | |
$909,129 | 37 | 42.19% | $127.55M | |
$35,190,048 | 32 | 37.32% | $150.49M |
Increased Positions | 63 | +44.68% | 5M | +8.36% |
Decreased Positions | 57 | -40.43% | 5M | -8.28% |
New Positions | 23 | New | 1M | New |
Sold Out Positions | 21 | Sold Out | 873,156 | Sold Out |
Total Postitions | 147 | +4.26% | 56M | +0.09% |
Bellevue Group Ag | $24,428.00 | 15.76% | 9.93M | 0 | 0% | 2024-12-31 |
Armistice Capital, Llc | $15,439.00 | 9.96% | 6.28M | +18,000 | +0.29% | 2024-12-31 |
Blackrock, Inc. | $12,441.00 | 8.03% | 5.06M | -348,297 | -6.44% | 2024-12-31 |
Vanguard Group Inc | $10,619.00 | 6.85% | 4.32M | -40,859 | -0.94% | 2024-12-31 |
Wasatch Advisors Lp | $8,582.00 | 5.54% | 3.49M | +952,691 | +37.57% | 2024-12-31 |
Frazier Life Sciences Management, L.P. | $7,812.00 | 5.04% | 3.18M | +164,938 | +5.48% | 2024-12-31 |
Millennium Management Llc | $7,047.00 | 4.55% | 2.86M | -671,179 | -18.98% | 2024-12-31 |
State Street Corp | $3,598.00 | 2.32% | 1.46M | +35,142 | +2.46% | 2024-12-31 |
Geode Capital Management, Llc | $3,526.00 | 2.28% | 1.43M | +26,341 | +1.87% | 2024-12-31 |
Acadian Asset Management Llc | $3,176.00 | 2.05% | 1.29M | +199,098 | +18.23% | 2024-12-31 |